XUHC:SW:SW-Xtrackers MSCI USA Health Care UCITS ETF 1D CHF (USD)

ETF | Others |

Last Closing

USD 51.49

Change

+0.09 (+0.18)%

Market Cap

USD 0.81B

Volume

141.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
RGLDS:SW Raiffeisen ETF Solid Gold A US..

+3.00 (+0.04%)

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-12.00 (-0.25%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-4.20 (-0.28%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

-1.00 (-0.05%)

USD 134,034.85B
SX7EEX:SW iShares EURO STOXX Banks 30-15..

+0.10 (+0.71%)

USD 6,289.31B
TDXPEX:SW iShares TecDAX® UCITS ETF (DE..

-0.01 (-0.02%)

USD 5,933.97B
SMIEX:SW iShares SLI UCITS ETF (DE)

+0.80 (+0.61%)

USD 5,933.96B
DJSXE:SW iShares Core EURO STOXX 50 UCI..

N/A

USD 5,933.96B
DAXEX:SW iShares Core DAX® UCITS ETF (..

+0.90 (+0.60%)

USD 5,933.93B
MDAXEX:SW iShares MDAX® UCITS ETF (DE) ..

+0.75 (+0.35%)

USD 5,933.92B

ETFs Containing XUHC:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.02% 76% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.02% 76% C+ 76% C+
Trailing 12 Months  
Capital Gain -3.94% 10% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.94% 10% F 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.33% 14% F 17% F
Dividend Return -1.33% 14% F 17% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 3.74% 65% D 70% C-
Risk Adjusted Return -35.61% 17% F 17% F
Market Capitalization 0.81B 74% C 70% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.